CTIS2024-514672-41-00
Recruiting
Phase 1
The Impact of Inhaled Furosemide and Perorally Administered Levodropropizine on Dyspnea in Patients With Advanced Respiratory Diseases (INFURO) - INFURO_2023
Fakultni Nemocnice Hradec Kralove0 sites114 target enrollmentJune 28, 2024
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Fakultni Nemocnice Hradec Kralove
- Enrollment
- 114
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age \= 18 years, Ability to understand the essence of the study and express consent to the study by signing the Informed Consent form, The patient's ability to assess dyspnea on the visual\-analog scale (VAS) and on the Borg scale, The presence of lung disease (asthma, chronic obstructive pulmonary disease, interstitial lung disease, oncological disease with lung involvement, patients with dyspnea after COVID19, drug\-induced dyspnea, lung infection) leading to acute or chronic dyspnea, which will currently be screened for the study assessed by the patient on the visual analog scale (VAS) with a value of 50 points and more and/or on the Borg scale with a value of 5 points and more, In the case of a woman of childbearing age, consent to abstain from sexual intercourse for the duration of participation in the study (i.e. for the duration of hospitalization). Note For evaluation purposes, menarche is considered to be the beginning of childbearing age, and the end is considered to be the end of the 12th month of amenorrhea from the last menstruation (menopause) at the usual age for the physiological cessation of ovarian function.
Exclusion Criteria
- •Hypersensitivity to the medicinal substance or to any auxiliary substance of furosemide or levodropropizine, The presence of COVID\-19, if it is not possible to ensure that all study activities are carried out in isolation from other patients, including entries in the source and study documentation, meeting the currently valid hygiene regulations, Hypersensitivity to sulfonamides (e.g. to sulfonylurea derivatives or to sulfonamide antibiotics), Severe hypokalemia, Severe hyponatremia, Hypovolemia and with or without hypotension, Dehydration, Disorder of mucociliary clearance (Kartagener's syndrome, ciliary dyskinesia), Severe liver disorders in Child Pugh stage B – C cirrhosis, Renal insufficiency with clearance \< 35 ml/min, Unstable patient requiring frequent changes or adjustments in medication and treatment, Patients on continuous i.v. medication or with the need to adjust therapy more than once every 4 hours, Ineligibility to participate in all study procedures, Pregnancy, breastfeeding, Participation in another clinical trial involving the administration of an investigational medicinal product within 28 days (or 5 half\-lives, whichever is longer) prior to screening
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
Compare effect of furosemide inhalation versus placebo in patients with acute cardiogenic pulmonary edemaAcute pulmonary oedema.Left ventricular failureIRCT2017101436753N1Vice chancellor for research, Iran University of Medical Sciences120
Not yet recruiting
Phase 3
Evaluation of the effectiveness of inhaled furosemide in patients with acute asthma attackIRCT20180522039784N2Karaj University of Medical Sciences90
Completed
Phase 3
Efficacy of nebulization salbutamol versus Efficacy of nebulization combination of salbutamol and furosemide in wheezing childHealth Condition 1: J989- Respiratory disorder, unspecifiedCTRI/2020/08/026975Government Medical College Aurangabad100
Not yet recruiting
Phase 3
Effect of nebulised furosemide on breathlessness and cough in interstitial lung disease: a pilot studyACTRN12619001032145Hunter New England Health12
Active, not recruiting
Phase 1
Study of efficacy and safety of diuretic administered with saline solution in the patient who presents decompensation of heart failure and does not require hospitalization.Decompensated Heart FailureMedDRA version: 20.0Level: LLTClassification code 10010684Term: Congestive heart failureSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2019-002852-17-ESMarta Cobo Marcos168